High expression of survivin in sacral chordoma

Medical Oncology

Volumn 30, Issue 2, 2013, Pages

  Chen, Chao ^a   Yang, Hui Lin ^a   Chen, Kang Wu ^a   Wang, Gen Lin ^a   Lu, Jian ^a   Yuan, Quan ^a   Gu, Yong Ping ^a   Luo, Zong Ping ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

Chordoma; Recurrence; Sacrum; Survival time; Survivin

Indexed keywords

SURVIVIN; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; TUMOR MARKER;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER RECURRENCE; CHORDOMA; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE TARGETING; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SACRAL CHORDOMA; TUMOR VOLUME; ADOLESCENT; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SACRUM; SPINAL CORD TUMOR; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; CHORDOMA; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; RETROSPECTIVE STUDIES; SACRUM; SPINAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84874934503     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0529-4     Document Type: Article

References (23)

1. McMaster ML, Goldstein AM, Bromley CM, et al. Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control. 2001;12(1):1-11.
2. Chandawarkar RY. Sacrococcygeal chordoma: review of 50 consecutive patients. World J Surg. 1996;20(6):717-9.
3. Fuchs B, Dickey ID, Yaszemski MJ, et al. Operative management of sacral chordoma. J Bone Joint Surg Am. 2005;87(10):2211-6.
4. Edlin BR, Tokars JI, Grieco MH, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med. 1992;326(23):1514-21.
5. Yang HL, Zhu LF, Liu JY, et al. Surgical treatment of sacral chordomas with preoperative arterial embolization and prognostic indicators of outcome. Spine J. 2007;5(7):34S.
6. Guzman JR, Fukuda S, Pelus LM. Inhibition of caspase-3 by Survivin prevents Wee1 Kinase degradation and promotes cell survival by maintaining phosphorylation of p34Cdc2. Gene Ther Mol Biol. 2009;13B:264-73.
7. Chiou SK, Jones MK, Tarnawski AS. Survivin-an anti-apoptosis protein: its biological roles and implications for cancer and beyond. Med Sci Monit. 2003;9(4):PI25-9.
8. Mesri M, Morales-Ruiz M, Ackermann EJ, et al. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol. 2001;158(5):1757-65.
9. Lu CD, Altieri DC, Tanigawa N. Expression of a novel anti-apoptosis gene, Survivin, correlated with tumor cell apoptosis and P53 accumulation in gastric carcinomas. Cancer Res. 1998;58(9):1808-12.
10. Naka T, Boltze C, Samii A, et al. Skull base and nonskull base chordomas: clinicopathologic and immunohistochemical study with special reference to nuclear pleomorphism and proliferative ability. Cancer. 2003;98(9):1934-41.
11. Favre J, Deruaz JP, Uske A. Skull base chordomas: presentation of six cases and review of the literature. J Clin Neurosci. 1994;1(l):7-18.
12. Hulen CA, Temple HT, Fox WP, et al. Oncologic and functional outcome following sacrectomy for sacral chordoma. J Bone Joint Surg Am. 2006;88(7):1532-9.
13. Hanna SA, Aston WJ, Briggs TW, et al. Sacral chordoma: can local recurrence after sacrectomy be predicted ? Clin Orthop Relat Res. 2008;466(9):2217-23.
14. Miettinen M, Lehto VP, Virtanen I. Malignant fibrous histiocytoma within a recurrent chordoma. A light microscopic, electron microscopic, and immunohistochemical study. Am J Clin Pathol. 1984;82(6):738-43.
15. Chen KW, Yang HL, Lu J, et al. Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma. J Neuro Oncol. 2011;101(3):357-63.
16. Chen KW, Yang HL, Lu J, et al. Risk factors for postoperative wound infections of sacral chordoma after surgical excision. J Spinal Disord Tech. 2011;24(4):230-4.
17. Hanna SA, Aston WJ, Briggs TW, et al. Sacral chordoma: can local recurrence after sacrectomy be predicted? Clin Orthop Relat Res. 2008;466:2217-23.
18. Olie RA, Simões-Wüst AP, Baumann B, et al. A novel antisense oligonucleotide targeting survivin expression induces and sensitizes apoptosis lung cancer cell to chemotherapy. Cancer Res. 2000;60(11):2805-9.
19. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998;58:5315-20.
20. Span PN, Sweep FC, Wiegerinck ET, et al. Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chem. 2004;50:1986-93.
21. Johnson ME, Howerth EW. Survivin: a bifunctional inhibitor of apoptosis protein. Vet Pathol. 2004;41:599-607.
22. Simpson AH, Porter A, Davis A, et al. Cephalad sacral resection with a combined extended ilioinguinal and posterior approach. J Bone Joint Surg Am. 1995;77(3):405-11.
23. Sundaresan N, Galicich JH, Chu FC, et al. Spinal chordomas. J Neurosurg. 1979;50:312-9.